Aldeyra Therapeutics (NASDAQ:ALDX) announces that the FDA has signed off on a 30-subject Phase 2 clinical trial evaluating ADX-629 in hospitalized adult COVID-19 patients.
Participants will be enrolled upon hospitalization for the respiratory illness and will receive ADX-629 or placebo twice per day for up to 28 days (on top of standard of care treatment). Key objectives include the NIAID COVID-19 scale and levels of cytokines and and reactive aldehyde species (RASP).
ADX-629 is an orally available RASP inhibitor that works upstream to modulate the immune system from a pro-inflammatory state to an anti-inflammatory state.
Mid-stage studies in psoriasis and atopic asthma should launch next quarter.
https://seekingalpha.com/news/3612458-aldeyra-on-go-mid-stage-study-of-adxminus-629-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.